Invivo Partners

Invivo Partners company information, Employees & Contact Information

Explore related pages

Related company profiles:

Invivo Partners promoted by Albert Ferrer and Luis Pareras, is a management company investing in early stages companies in the healthcare sector. Invivo Partners has a team of highly qualified professionals, with the scientific, technical and financial know-how required to analyse and make investments to provide value to the invested company. It also has a network of contacts and key strategic relationships in the health ecosystem. Invivo Ventures is managed by Invivo Partners, promoted by Luis Pareras and Albert Ferrer, with the experience gained through the first fund Healthequity. The fund was registered to the Comisión Nacional del Mercado de Valores (CNMV) in March 2019 and has achieved a final closing of 60M €. We are a team of highly qualified professionals, with the scientific, technical and financial know-how required to analyse and make investments to provide value to the invested company. We also have a network of contacts and key strategic relationships in the health ecosystem. Our company is financed by the European Investment Fund, the Instituto de Crédito Oficial, the Institut Català de Finances, the Institut Valencià de Finances, the Ajuntament de Barcelona and other private investors. Two successful exits from our first fund in 2022, validating our early-stage investment thesis focused on extraordinary science in leading-edge fields that are to play a role in the future of medicine. Our portfolio companies from the first fund have raised >220M€ from international VCs. Our knowledge of the Technology Transfer space plus our ability to identify new market trends and create biotech companies opens the opportunity to become one of the major players in Technology Transfer in Europe.

Company Details

Employees
12
Founded
-
Address
Barcelona, Barcelona 08007, Es
Industry
Venture Capital And Private Equity Principals
NAICS
Miscellaneous Intermediation
Keywords
San Sebastián.
HQ
Barcelona, Barcelona
Looking for a particular Invivo Partners employee's phone or email?

Invivo Partners Questions

News

Invivo Partners Prepares the Launch of a €100M Fund at the Intersection of AI and Science and Welcomes Pep Martorell as Partner - AI Insider

Invivo Partners Prepares the Launch of a €100M Fund at the Intersection of AI and Science and Welcomes Pep Martorell as Partner AI Insider

Integra Therapeutics secures €10.7 million investment round to advance development of FiCAT gene writing platform and preclinical validation of CAR-T therapies - BioSpace

Integra Therapeutics secures €10.7 million investment round to advance development of FiCAT gene writing platform and preclinical validation of CAR-T therapies BioSpace

Invivo aims to raise €100M for fourth fund; SEED Therapeutics gets $30M - Endpoints News

Invivo aims to raise €100M for fourth fund; SEED Therapeutics gets $30M Endpoints News

Kite to Acquire Interius BioTherapeutics to Advance In Vivo Platform - Business Wire

Kite to Acquire Interius BioTherapeutics to Advance In Vivo Platform Business Wire

Covington & Burling counsels AstraZeneca on biotech company acquisition - ICLG.com

Covington & Burling counsels AstraZeneca on biotech company acquisition ICLG.com

European VC Invivo readies its latest fund to back new biotechs - BioPharma Dive

European VC Invivo readies its latest fund to back new biotechs BioPharma Dive

Stylus Medicine Launches to Develop Precision, In Vivo Genetic Medicines and Unlock the Full Potential of CAR-T Therapy - BioSpace

Stylus Medicine Launches to Develop Precision, In Vivo Genetic Medicines and Unlock the Full Potential of CAR-T Therapy BioSpace

Graham Norton backed Invivo Wines on potential for new capital raise - BusinessDesk | NZ

Graham Norton backed Invivo Wines on potential for new capital raise BusinessDesk | NZ

France's InVivo offers close to $1 bln for Australia's United Malt - Reuters

France's InVivo offers close to $1 bln for Australia's United Malt Reuters

In vivo CAR T cell generation to treat cancer and autoimmune disease - Science | AAAS

In vivo CAR T cell generation to treat cancer and autoimmune disease Science | AAAS

ARTHEx Biotech Announces Closing of €42 M Series B Financing to Advance ATX-01, its Novel Treatment for Myotonic Dystrophy Type 1 (DM1) - PR Newswire

ARTHEx Biotech Announces Closing of €42 M Series B Financing to Advance ATX-01, its Novel Treatment for Myotonic Dystrophy Type 1 (DM1) PR Newswire

A new cancer immune therapy spin-off of Hospital Clínic-IDIBAPS secures a 1.5 million-euro inve - Hospital Clínic Barcelona

A new cancer immune therapy spin-off of Hospital Clínic-IDIBAPS secures a 1.5 million-euro inve Hospital Clínic Barcelona

Jeito Capital co-leads EUR 65 million (USD 71 M) financing in Corteria Pharmaceuticals, a French biopharmaceutical company developing novel treatments for cardiovascular diseases - Yahoo Finance

Jeito Capital co-leads EUR 65 million (USD 71 M) financing in Corteria Pharmaceuticals, a French biopharmaceutical company developing novel treatments for cardiovascular diseases Yahoo Finance

In vivo human T cell engineering with enveloped delivery vehicles - Nature

In vivo human T cell engineering with enveloped delivery vehicles Nature

Fierce Biotech Fundraising Tracker '23: Carmot spinoff Kimia raises $55M; Lassen fuels for fibro-inflammatory mission - Fierce Biotech

Fierce Biotech Fundraising Tracker '23: Carmot spinoff Kimia raises $55M; Lassen fuels for fibro-inflammatory mission Fierce Biotech

New gene-writing technology to obtain more effective and safe therapies developed - EurekAlert!

New gene-writing technology to obtain more effective and safe therapies developed EurekAlert!

Indevin Group takes nearly 15% stake in Invivo Wines - BusinessDesk | NZ

Indevin Group takes nearly 15% stake in Invivo Wines BusinessDesk | NZ

Exclusive: China biotech raises $44M to advance in vivo CAR-T programs after early clinical data - Endpoints News

Exclusive: China biotech raises $44M to advance in vivo CAR-T programs after early clinical data Endpoints News

France’s InVivo aims to become top world malt producer after Soufflet takeover - Reuters

France’s InVivo aims to become top world malt producer after Soufflet takeover Reuters

Winemaker Invivo calls in advisers to ensure it remains 'well-funded and agile' - BusinessDesk | NZ

Winemaker Invivo calls in advisers to ensure it remains 'well-funded and agile' BusinessDesk | NZ

Chinese biotech says it will start first in vivo beta-thalassemia trial - statnews.com

Chinese biotech says it will start first in vivo beta-thalassemia trial statnews.com

Capstan heats up ‘in vivo’ cell therapy chase with $175M fundraise - BioPharma Dive

Capstan heats up ‘in vivo’ cell therapy chase with $175M fundraise BioPharma Dive

A new spin-off company to develop the first treatment against pulmonary fibrosis based on telomerase gene therapy - Centro Nacional de Investigaciones Oncológicas - CNIO

A new spin-off company to develop the first treatment against pulmonary fibrosis based on telomerase gene therapy Centro Nacional de Investigaciones Oncológicas - CNIO

Editas prioritizes in vivo gene therapies, looks to partner reni-cel - Fierce Biotech

Editas prioritizes in vivo gene therapies, looks to partner reni-cel Fierce Biotech

Fourteen spin-offs to participate in the Arquimedes acceleration programme - uab.cat

Fourteen spin-offs to participate in the Arquimedes acceleration programme uab.cat

Endpoints 11 winner Capstan Therapeutics: Trying to win the in vivo CAR-T race - Endpoints News

Endpoints 11 winner Capstan Therapeutics: Trying to win the in vivo CAR-T race Endpoints News

AstraZeneca pays up to $1bn for biotech firm ‘that could transform cell therapy’ - The Guardian

AstraZeneca pays up to $1bn for biotech firm ‘that could transform cell therapy’ The Guardian

InVivo Completes US$2.5B Takeover of Soufflet; KKR, Bpifrance, Credit Agricole Invest EUR440M For Majority of Malt Unit - Global AgInvesting

InVivo Completes US$2.5B Takeover of Soufflet; KKR, Bpifrance, Credit Agricole Invest EUR440M For Majority of Malt Unit Global AgInvesting

New spin-off to develop the first gene therapy-based pulmonary fibrosis treatment - uab.cat

New spin-off to develop the first gene therapy-based pulmonary fibrosis treatment uab.cat

Manifold Bio Raises $40 Million Series A to Expand In Vivo Biologics Design Platform - Business Wire

Manifold Bio Raises $40 Million Series A to Expand In Vivo Biologics Design Platform Business Wire

Nvelop Therapeutics Launches with Dual Platforms for In Vivo Delivery of the Next Generation of Genetic Medicines - Business Wire

Nvelop Therapeutics Launches with Dual Platforms for In Vivo Delivery of the Next Generation of Genetic Medicines Business Wire

Invivo Wines looks to raise $6.5m capital - NZ Herald

Invivo Wines looks to raise $6.5m capital NZ Herald

Top Invivo Partners Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant